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A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris
Supplementary file Methods
Study design
A safety follow-up visit was scheduled 2 weeks after week 4 in the event of an ongoing adverse event (AE) with a possible, probable or not assessable relationship to study medication, or in the event of elevated albumin-corrected serum calcium levels or clinically significant abnormal values of another laboratory parameter at week 4. A safety follow-up visit was scheduled 4 weeks after study day 28 in the event of abnormal results on the adrenocorticotropic hormone (ACTH) challenge test (serum cortisol ≤497 nmol/L 30 minutes after ACTH challenge test), wherein another ACTH challenge test would be performed at the follow-up visit.
Exclusions and washouts
Patients were excluded from the trial if they had a history of allergic asthma, serious allergy, serious allergic skin rash or known/suspected hypersensitivity to any of the agents applied during the study. 
Figure. Study design
Day 0 is treatment baseline; SV2 is considered the same as baseline for laboratory tests.
FU, follow-up; SV, screening visit.
Cortisol assay
The cortisol assay used was the Siemens ADVIA Centaur ® XP, which had an assay precision of 5.5% coefficient of variation. The analytic range was 5.5-2070 nmol/L and the sensitivity was 5.5 nmol/L.
Statistical analysis
It was calculated that with this sample size, the upper limit of an exact 95% confidence interval would be 12% of the risk of a patient experiencing serum cortisol levels ≤497 nmol/L 30 minutes after the ACTH challenge test, assuming that the event was not observed for any of the 30 patients.
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